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Abstract
Background: The Fc glycosylation of immunoglobulin G (IgG) is well known to associate with rheumatoid arthritis
(RA) disease activity. The same may be true for other classes of Igs. In the present study, we sought to determine
whether the glycosylation of IgA was different between healthy subjects and patients with RA, as well as whether
it was associated with RA disease activity, in particular with the pregnancy-associated improvement thereof or
the flare after delivery.
Methods: A recently developed high-throughput method for glycoprofiling of IgA1 was applied to affinity-captured
IgA from sera of patients with RA (n = 252) and healthy control subjects (n = 32) collected before, during and after
pregnancy.
Results: IgA1 O-glycans bore more sialic acids in patients with RA than in control subjects. In addition, levels of
bisecting N-acetylglucosamine of the N-glycans at asparagine 144 were higher in the patients with RA. The levels of
several N-glycosylation traits were shown to change with pregnancy, similar to what has been shown before for IgG.
However, the changes in IgA glycosylation were not associated with improvement or a flare of disease activity.
Conclusions: The glycosylation of IgA differs between patients with RA and healthy control subjects. However, our
data suggest only a minor, if any, association of IgA glycosylation with RA disease activity.
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Background
In rheumatoid arthritis (RA), autoantibodies such as
rheumatoid factor (RF) and anti-citrullinated peptide
antibodies (ACPA) are thought to be crucial not only in
initiating the disease process of RA but also in the more
chronic stages [1–4]. Representatives of the immuno-
globulins G, A and M (IgG, IgA and IgM, respectively)
have been recognised for RF as well as ACPA [2, 3, 5].
Besides autoantibodies, sex hormones are thought to
have an important role in the pathogenesis of RA, as can
be illustrated by the spontaneous improvement of RA
during pregnancy [6, 7].
Antibodies are glycoproteins, meaning that they bear
at least one glycan on the protein backbone [8]. Glycans
may influence immunological properties of antibodies
by affecting, for example, receptor binding, half-life, or
binding of complement [9, 10]. There are two main
classes of glycans described for antibodies, namely the
N-linked glycans (linked to a nitrogen atom, or N) and
the O-linked glycans (linked to an oxygen atom, or O).
The N-glycans can be found at the asparagine in a
known consensus sequence, Asn-Xxx-Ser/Thr, where
Xxx can be any amino acid except proline, whereas O-
linked glycans can be linked to serine or threonine resi-
dues, generally in a proline-rich region.
During pregnancy N-glycosylation changes have been
described for several individual serum proteins, such as
alpha-1-antitrypsin, alpha-1-acid glycoprotein, IgG and
IgA, as well as for released total serum N-glycans [11–15].
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For IgG-Fc, bearing almost exclusively N-linked glycans,
these changes during pregnancy and after delivery were
shown to be associated with RA disease activity and the
pregnancy-associated improvement thereof [16, 17]. These
associations were not observed for the glycans on the
variable domain of IgG [18]. For the glycosylation of
the other Igs, little is known concerning the association
with RA and the pregnancy-associated improvement of
RA disease activity. However, given the evident role of
antibodies in RA, this information has a high relevance.
Indications for a potential pathogenic role of IgA in
RA are given by studies demonstrating the association of
IgA RF autoantibodies with bone erosions in RA [19,
20]. Similarly, patients with RA who are seropositive for
both IgG- and IgA-ACPA have a more severe disease
course than patients with only IgG-ACPA [21].
There are two subclasses of IgA, of which IgA1 is the
most abundant (approximately 90%) in the human cir-
culation. Whereas most Ig isotypes carry only N-linked
glycans, the IgA1 subclass carries in addition between
three and six O-linked glycans [22, 23]. The O-glycans
are present in the hinge region of IgA1 and consist of
one N-acetylgalactosamine (GalNAc), which can be
decorated by a galactose (Gal) (Fig. 1). Furthermore,
sialic acids (SAs) may be attached to either the Gal or
the GalNAc. There are two N-glycosylation sites on
IgA1 (Asn144 and Asn340), and the glycans are of the
diantennary complex type, generally consisting of a
core of four N-acetylglucosamines (GlcNAcs), three
mannoses and two Gals. This core structure can be
decorated by one or two SAs, one fucose, or one bisect-
ing GlcNAc (Fig. 1) [11, 15, 24–26]. The addition of
fucose has been shown to occur only at Asn340 [25]. In
addition, low amounts of triantennary glycans can be
detected at this site.
Disease-associated IgA O-glycosylation changes have
been demonstrated in several IgA-related diseases, such
as IgA nephropathy, Henoch-Schönlein purpura, Wiskott-
Aldrich syndrome and X-linked thrombocytopenia, for
which decreased levels of Gal on the O-glycans were
observed [27–29]. For RA, the published data are less
clear, mainly owing to small sample size and to the ap-
plied techniques with only a low level of detail. Up to
now, it has been suggested that in RA (n = 26), the
number of Gals on the O-glycans is similar to that in
control subjects, whereas the level of GalNAc is de-
creased [30]. The level of GalNAc on the IgA O-gly-
cans was found to be associated with the level of
galactosylation on the N-glycans of IgG. With regard
to IgA1 N-glycosylation in RA, no differences were
found in comparison to healthy individuals (n = 5 for
both groups) [24].
However, to study the relevance of IgA glycosylation
in association with RA disease activity and pregnancy-
induced improvement thereof, larger numbers of sam-
ples need to be analysed in detail, as we have previously
reported for IgG [16]. For this purpose, we recently de-
veloped a high-throughput technique for site-specific
analysis of both IgA N- as well as O-glycosylation [15].
By applying this method, we have been able to show
pregnancy-associated changes both in N- and O-glyco-
sylation of IgA in a cohort of healthy women. In the
present study, we applied this method to the RA sam-
ples collected within the framework of the Pregnancy-
induced Amelioration of Rheumatoid Arthritis (PARA)
study. The total set consists of approximately 1600
Fig. 1 Schematic representation of immunoglobulin A (IgA) and IgG and the sites of their respective glycosylation sites as can be detected by
glycopeptide analysis of serum-derived samples. Insets show schematic representations of an O-glycan, an N-glycan and a potential configuration
of an O-glycopeptide. No linkage information is intended by any position of a monosaccharide
Bondt et al. Arthritis Research & Therapy  (2017) 19:160 Page 2 of 8
samples obtained from pre-pregnancy onwards from
both healthy control subjects and patients with RA.
These samples can be used to study differences be-
tween healthy control subjects and patients with RA,
the association of IgA glycosylation with disease activity
in the non-pregnant state, as well as for research on
the improvement during pregnancy and flare after de-
livery and its association with IgA glycosylation.
Methods
Study population
The present research is embedded in the PARA study,
a nationwide prospective cohort study on pregnancy
and RA (n = 253) from pre-pregnancy onwards [7, 16].
Healthy control subjects (n = 32) were included as a
reference group [16]. The study was carried out in com-
pliance with the Helsinki declaration and was approved
by the ethics review board at the Erasmus University
Medical Centre, Rotterdam, The Netherlands. This study
has been described in detail elsewhere [7].
Categorisation of disease activity and clinical response
Disease activity was assessed using the Disease Activity
Score in 28 joints (DAS28) based upon C-reactive pro-
tein, as well as swollen and tender joint counts [31].
Responders and non-responders were categorised
based upon the European League Against Rheumatism
(EULAR) response criteria [32]. The response was
defined between the first and third trimesters. A post-
partum flare was defined according to the so-called
reversed EULAR response criteria [7]. The flare was
defined between 6 and 26 weeks post-partum.
IgA sample preparation and measurement
Site-specific IgA glycosylation analysis was performed
as described previously [15]. Briefly, IgA was captured
from 10 μl of human serum or plasma using Capture-
Select IgA Affinity Matrix beads (Life Technologies
Europe, Bleiswijk, The Netherlands) in 96-well format.
After elution from the beads, the samples were dried,
followed by overnight digestion at 37 °C with L-1-p-
tosylamino-2-phenylethyl chloromethyl ketone-treated
trypsin (Sigma-Aldrich, Steinheim, Germany) after re-
duction/alkylation.
Obtained trypsin digestions of IgA samples were
enriched for glycopeptides by two-step microtip cot-
ton hydrophilic interaction chromatography-based
solid phase extraction, using cotton thread as the solid
phase, as described previously [15]. Matrix-assisted
laser desorption/ionisation (MALDI) Fourier trans-
form ion cyclotron resonance (FTICR) mass spectrom-
etry (MS) measurements were performed as described
elsewhere [15].
Data extraction and curation
Data Analysis Software 4.0 software package 4 (Bruker
Daltonics, Billerica, MA, USA) was used for the visual-
isation and conversion of the MALDI spectra into.xy
files. The XY data of the MALDI-FTICR experiments
were internally recalibrated and integrated with a tool
developed in-house (MassyTools version 1.6.3.0) [33].
In addition, several quality measures were extracted.
After analyte and spectrum curation, several glycosyla-
tion traits were calculated as described in Additional
file 1: Supplementary Methods.
Statistical methods
Initial data exploration using SIMCA software (Sartorius
Stedim Data Analytics AB, Umeå, Sweden) showed minor
batch effects, which were corrected using the ComBat
batch correction in R (R Foundation for Statistical Com-
puting, Vienna, Austria). All other statistical tests were
performed using Stata/SE 13.1 for Windows software
(StataCorp LP, College Station, TX, USA). In the batch-
corrected data, we first investigated the differences
between patients with RA and healthy control subjects
in the non-pregnant state at 6 months post-partum
using a Mann-Whitney test. To study which covariates
were associated with the levels of the extracted N- and
O-glycosylation traits of patients with RA in the non-
pregnant state, multivariable linear regression analysis
was performed on the samples obtained at 26 weeks
post-partum. Covariates that were studied were the use
of prednisone, methotrexate, sulphasalazine, hydroxy-
chloroquine, leflunomide, or tumour necrosis factor
(TNF) inhibitors (all different TNF inhibitors grouped
together), as well as the DAS28, autoantibody (RF, ACPA
or both) seropositivity, and age at delivery.
The effects of pregnancy on the glycosylation traits was
studied using multi-level mixed-effects linear regression,
similarly to what has been described previously [16], but
using Stata software. Comparisons were made between
pre-conception and the third trimester (RA only), between
the first and third trimesters, between the third trimester
and 6 weeks post-partum, between the third trimester and
26 weeks post-partum, and between 6 and 26 weeks post-
partum (bisection only). In addition, we investigated pos-
sible differences in the pregnancy-associated glycosylation
changes between patients who do or do not improve dur-
ing pregnancy (responders and non-responders), as well as
between patients with or without a post-partum flare of
disease activity, as described previously [16].
Finally, we explored which glycosylation traits are as-
sociated with disease activity at each time point, using a
bootstrap approach for a multivariable linear regression
model. The pre-conception time point was excluded
owing to lack of power. The DAS28 was used as the
dependent variable, whereas the use of prednisone,
Bondt et al. Arthritis Research & Therapy  (2017) 19:160 Page 3 of 8
methotrexate, sulphasalazine, hydroxychloroquine, bio-
logics, or leflunomide, autoantibody (RF, ACPA, or
both) seropositivity, and age at delivery were treated as
fixed elements, and the calculated glycosylation traits (for
IgA as obtained in the present study, and for IgG obtained
in a previous study [16]) were selected as potential covari-
ates. One thousand rounds of backwards elimination with
a p < 0.05 cut-off were performed, after which a summary
of all models was prepared using the ten most often in-
cluded glycosylation variables. In all statistical tests, Bon-
ferroni multiple testing correction was performed when
applicable, as specified in the presented tables.
Results
Study population
Clinical characteristics of patients and healthy control
subjects are presented in Table 1.
IgA glycosylation in patients with RA and healthy control
subjects in the non-pregnant state
Site-specific differences in glycosylation between patients
and control subjects
The difference between patients with RA and healthy in-
dividuals was tested ≥6 months post-partum, when the
women had ‘recovered’ from pregnancy, to exclude po-
tentially differential influences of pregnancy on the gly-
cosylation of IgA for patients as compared with control
subjects. For the majority of the calculated glycosylation
traits, no difference was observed between patients and
control subjects (Table 2). However, the number of SAs
on the O-glycans was significantly higher in patients
with RA (3.1, SD 0.18) than in healthy control subjects
(3.0, SD 0.14; p = 0.0023). For the N-glycosylation at
Asn144, the level of bisecting GlcNAc was higher in pa-
tients (32.0%, SD 8.1%) than in the control subjects
(26.3%, SD 4.1%; p = 0.0001) (Table 2).
Association of IgA glycosylation with clinical variables
To determine which clinical parameters were associated
with IgA glycosylation in patients with RA in the non-
pregnant state (at 6 months post-partum), multivariable
linear regression analyses were performed, using the gly-
cosylation traits as dependent variables and several clinical
parameters as independent variables. No models remained
significant after Bonferroni correction (p < 0.0039). The
best model was bisection of the N-glycans at Asn340
(trunc.; p = 0.0042, R2 = 0.12), suggesting positive asso-
ciations of disease activity (β = 0.21), use of prednisone
Table 1 Cohort characteristics
Healthy control
subjects (n = 32)
Pregnant patients
with RA (n = 252)
Mean age at delivery in
years (SD)
32.1 (4.4) 32.8 (3.7)
Median disease duration
in years at first visit (range)
4.9 (0.2-28.6)
ACPA-positive patients, n (%) 153/252 (61)
RF-positive patients, n (%) 161/239 (67)
ACPA- and/or RF-positive
patients, n (%)
181/252 (72)
Erosive disease, n (%) 150/246 (61)
Response during
pregnancya, n (%)
56/120 (47)
Flare during post-partum
period, n (%)
69/223 (31)
Per time point Pre-conception First
trimester
Second
trimester
Third
trimester
6 Weeks
post-partum
12 Weeks
post-partum
26 Weeks
post-partum
DAS28, mean (SD) 3.6 (1.1) 3.6 (1.1) 3.6 (1.1) 3.3 (1.1) 3.3 (1.1) 3.6 (1.2) 3.4 (1.1)
Use of prednisone, n (%) 37/121 (31) 79/223 (35) 86/234 (37) 81/239 (34) 84/240 (35) 87/242 (36) 78/242 (32)
Use of sulphasalazine, n (%) 41/121 (34) 62/223 (28) 64/234 (27) 61/239 (26) 60/240 (25) 72/242 (30) 70/242 (29)
Use of hydroxychloroquine,
n (%)
9/121 (7) 5/223 (2) 5/234 (2) 4/239 (2) 9/240 (4) 18/242 (7) 17/242 (7)
Use of methotrexate, n (%) 0/121 (0) 0/223 (0) 0/234 (0) 0/239 (0) 34/240 (14) 59/242 (24) 74/242 (31)
Use of leflunomide, n (%) 0/121 (0) 0/223 (0) 0/234 (0) 0/239 (0) 0/240 (0) 3/242 (1) 4/242 (2)
Use of TNF inhibitors, n (%) 5/121 (4) 0/223 (0) 0/234 (0) 0/239 (0) 13/240 (5) 23/242 (10) 29/242 (12)
Abbreviations: ACPA Anti-citrullinated peptide antibodies, DAS28 Disease Activity Score in 28 joints, RA Rheumatoid arthritis, RF Rheumatoid factor, TNF Tumour
necrosis factor
aThe European League Against Rheumatism response criteria require a DAS28 > 3.2 at baseline
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(β = 0.21) and age at delivery (β = 0.16) (Additional file 2:
Table S1) with bisection.
Pregnancy-associated IgA glycosylation changes
Pregnancy-associated changes were studied using multi-
level mixed-effects linear regression models. For the
healthy control subjects, the results were similar to those
of our previously published work [15], with only minor
differences in significance due to a different statistical
method and different p value cut-off. For the patients
with RA, all N- and O-glycosylation variables, except for
sialylation at the intact Asn340, showed pregnancy-
associated changes (Additional file 2: Table S2). The O-
glycans showed an increase in levels of GalNAc during
pregnancy, as well as increased levels of Gals, SAs and
increased ratios of SAs per Gal and Gals per GalNAc
after delivery. All changes were minor (0.3–2% increase).
At N-glycosylation site Asn144, an increase (1.04-fold)
of sialylation was observed during pregnancy, and a
decrease (0.96-fold) was observed after delivery. The bi-
section at this site showed an increase during pregnancy
(1.05- up to 1.09-fold), which persisted until 6 weeks
post-partum. At Asn340, similar trends were observed,
although the effect size for sialylation was tenfold
smaller, whereas the pregnancy-associated changes in bi-
section appear to be slightly more pronounced. Fucosy-
lation, which is not present at Asn144, showed a slight
decrease with pregnancy (0.99-fold), and an increase was
observed after delivery (1.01-fold). The most pronounced
changes were observed for the low levels triantennary
glycans at Asn340, which increased 1.10-fold during
pregnancy and showed a 0.90-fold down to 0.86-fold
decrease post-partum. For all glycosylation traits, the
observed changes were highly similar between patients
with RA and healthy control subjects.
For the non-truncated Asn340 sialylation, and for
Asn144 and truncated Asn340 fucosylation, the mixed
model showed no deviating time points after Bonferroni
correction (Additional file 2: Table S2). The means for
each time point of all traits are depicted in Additional
file 2: Table S3 and graphically presented in Additional
file 3: Figures S1 and S2.
IgA glycosylation changes are not different between
responders and non-responders
To study whether the changes in IgA glycosylation
associate with the improvement of RA disease activity
during pregnancy (the response) and the worsening of
it post-partum (the flare), Wilcoxon rank-sum tests
were performed for each calculated glycosylation trait.
No significant differences were identified.
Furthermore, we explored the association of IgA as
well as IgG glycosylation traits with disease activity. In
the vast majority of the models, IgG glycosylation traits
were found to be associated with disease activity. Only
at the second and third trimesters of pregnancy was a
minor influence of IgA glycosylation observed. More
details of the results are described in Additional file 4:
Supplementary Results.
Discussion
This study shows that IgA glycosylation is different be-
tween patients with RA and healthy control subjects,
and also that pregnancy-associated changes in IgA
Table 2 Glycosylation comparison of healthy control subjects vs. patients with rheumatoid arthritis at the non-pregnant state
(≥26 weeks after delivery)
Healthy RA p
ValueMean SEM Mean SEM
O-glycosylation GalNAc, n 4.81 0.009 4.82 0.004 0.230
Gal, n 3.99 0.014 4.03 0.005 0.017
SAs, n 3.05 0.027 3.15 0.013 0.002
SAs per Gal 0.76 0.006 0.78 0.003 0.007
Gals per GalNAc 0.83 0.003 0.84 0.001 0.028
N-glycosylation Asn144 % Sialylation 60.37 0.854 58.09 0.388 0.039
% Bisection 26.27 0.784 32.04 0.604 <0.001
Asn340 Intact % Sialylation 95.68 0.170 95.17 0.106 0.097
Trunc. 89.82 0.173 90.13 0.086 0.104
Intact % Bisection 57.94 1.057 60.45 0.508 0.046
Trunc. 56.12 0.893 57.26 0.444 0.355
Trunc. % Fucosylation 93.57 0.304 92.98 0.134 0.055
Trunc. % Triantennary 5.30 0.298 4.97 0.119 0.136
Abbreviations: Gal Galactose, GalNAc N-acetylgalactosamine, RA Rheumatoid arthritis, SA Sialic acid, trunc. Truncated
Bonferroni-corrected p < 0.004 is considered significant, indicated by boldface type
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glycosylation traits occur in the patients in a similar
fashion as in the control subjects. However, these changes
were not associated with the pregnancy-induced im-
provement of RA.
Several differences in IgA N- and O-glycosylation be-
tween patients with RA and healthy control subjects
were observed. However, these changes showed only
minor effect sizes. Previously, it was shown for the IgA
O-glycosylation that the number of GalNAcs is lower in
patients with RA [30]. However, this was not confirmed
in our study. The most likely explanation lies in the fact
that we were able to observe more high-mass glycopep-
tides without losing the lower-mass region, causing the
differences in the number of GalNAcs (which would be
observed mainly in the lower-mass glycopeptides) to lose
significance. In contrast, we do show an increased level
of SAs on the O-glycans in patients with RA (1.03-fold),
which would be visible mainly in the high-mass region.
In the present study, we observed hardly any changes
with regard to O-glycosylation during pregnancy. How-
ever, for N-glycosylation, we have been able to show that
in patients with RA, several pregnancy-associated IgA
N-glycosylation changes do occur, similar to what we
have previously described for healthy control subjects
[15]. In addition, IgA N-glycosylation appears to show
pregnancy-associated changes which are comparable to
those observed for IgG-Fc, albeit at different levels [16].
Furthermore, differences between patients with RA and
healthy control subjects were observed, with lower levels
of N-glycan sialylation at Asn144 and increased levels of
bisecting GlcNAc on the N-glycans at both Asn144 and
Asn340. The higher level of bisection has been shown to
associate with a less favourable state in several diseases,
both on IgG and on cell surface glycans [34, 35]. Inter-
estingly, the pregnancy-associated time lapse for IgA bi-
section was slightly different from what was observed
previously for IgG, with an increase from the first tri-
mester onwards until the first post-partum time point,
only after which a decrease starts. For IgG, the levels of
bisection were relatively stable during pregnancy and
similarly stable (albeit at a higher level) after delivery
[16]. Thus, although the general pattern of pregnancy-
induced changes in glycosylation of serum IgA and
IgG—both produced predominantly by plasma cells—ap-
pears to be similar, the functional consequences might
be different for IgA compared with IgG and remain to
be elucidated.
Finally, we sought to gain more insight into the poten-
tial association of IgA glycosylation with RA disease
activity. The observed pregnancy-associated changes in
glycosylation did not differ between patients whose RA
disease activity improved during pregnancy and patients
whose disease activity did not improve, nor did they dif-
fer between patients with and without a post-partum
flare of disease activity. Furthermore, we explored this
association using multivariable linear regression analysis,
using disease activity as the dependent variable. Models
were built with a bootstrap approach of a backwards se-
lection procedure. For four of six time points, we found
IgG glycosylation to be the main or even the only signifi-
cant ‘predictor’. IgA glycosylation was significant only in
the second and third trimesters of pregnancy, with quite
small effect sizes. Altogether, our data strongly suggest a
more prominent association for IgG than for IgA with
disease activity, which may imply a more prominent role
for changes in IgG glycosylation in the pathogenesis of
RA and in the improvement of RA during pregnancy.
Nevertheless, the absence of associations of IgA glyco-
sylation with possible effects in the current setting of
RA and pregnancy does not exclude any role of IgA gly-
cosylation in IgA functionality.
Conclusions
We have demonstrated in a large dataset that there is a
difference in IgA glycosylation between patients with RA
and healthy control subjects, and also that the glycosyla-
tion of IgA changes during pregnancy. However, most
differences and changes were minor, so it is unlikely that
these have any biological significance. In addition, only
minor associations of IgA glycosylation with RA disease
activity were observed. This all suggests only a limited
role for IgA glycosylation in the pathogenesis of RA,
which is in sharp contrast to what has previously been
shown for IgG glycosylation. Nevertheless, other proper-
ties of IgA may still be important in the pathogenesis of
RA, such as the level of IgA plasmablasts [36].
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